Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftobiprole Medocaril vs Vancomycin + Aztreonam in ABSSSI
NCT03137173Phase 3Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Feb 2018
- Primary completion
- Apr 2019
- Modality
- Reversible Covalent Inhibitors
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of ceftobiprole medocaril in acute bacterial skin and skin structure infection (ABSSSI) (2 arms), sponsored by Basilea Pharmaceutica. Primary endpoint: Early Clinical Response. Started Feb 2018; status: completed.
02
Drugs
ceftobiprole medocaril
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT03137173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03137173.